15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering UroGen Pharma Ltd, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $33.00 to $50.00, a moderate spread. The average target of $41.20 sits 1% below the current $41.43. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.05 next quarter toward $1.49 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to UroGen Pharma Ltd.
As of Jul, 5 of 5 firms rate URGN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
URGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.05
Range $-0.37 – $0.16 · 8 analysts · -93% YoY
Next period, 8 analysts expect UroGen Pharma Ltd to earn $-0.05 a share (range $-0.37 – $0.16), versus $-0.69 a year earlier. Full-year consensus is $-0.70, growing to $1.49 the year after.
REVENUE · NEXT QUARTER
$75.6M
Range $66.2M – $87.5M · 8 analysts · +175% YoY
Revenue is expected to reach $75.6M (range $66.2M – $87.5M), +175.3% year-over-year. Full-year consensus is $276.5M, rising to $435.3M next year.
Top analysts covering UroGen Pharma Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on URGN.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$15.00-63.8% to target
Overall win rate
55%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$45.00+8.6% to target
Overall win rate
37%
+ Follow
#3
Leland Gershell
Oppenheimer · Rank #254
Buy
$50.00+20.7% to target
Overall win rate
37%
+ Follow
#4
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$33.00-20.3% to target
Overall win rate
22%
+ Follow
#5
Aydin Huseynov
Ladenburg Thalmann · Rank #361
Buy
$31.00-25.2% to target
Overall win rate
34%
+ Follow
URGN stock forecast FAQ
What is URGN's average 12-month price target?+
The 5 analysts with a live target average $41.20 for UroGen Pharma Ltd over the next 12 months, ranging from a $50.00 high to a $33.00 low.
Is URGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for URGN?+
The Street-high target is $50.00 (Oppenheimer), and the Street-low is $33.00 (D. Boral Capital). The average of all 5 active targets is $41.20.
How many Wall Street analysts cover URGN?+
5 analysts have an active rating on UroGen Pharma Ltd, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering URGN?+
Among analysts who currently cover URGN, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $15.00 target.
What is UroGen Pharma Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.05 per share (range $-0.37 – $0.16) across 8 analysts. Full-year EPS is projected at $-0.70, rising to $1.49 the following year.
How much revenue is UroGen Pharma Ltd expected to report next quarter?+
Consensus revenue is $75.6M (range $66.2M – $87.5M). Full-year revenue is projected at $276.5M, growing to $435.3M next year.
Have analysts been upgrading or downgrading URGN lately?+
As of Jul, 5 of 5 firms rate URGN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their URGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
